ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $70.00 to $73.00. On average, they expect the company's share price to reach $71.67 in the next year. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

ANI Pharmaceuticals' stock was trading at $40.23 at the start of the year. Since then, ANIP shares have increased by 46.4% and is now trading at $58.91.
View the best growth stocks for 2023 here.

ANI Pharmaceuticals saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 264,800 shares, a decrease of 7.5% from the August 15th total of 286,200 shares. Based on an average daily trading volume, of 156,800 shares, the short-interest ratio is currently 1.7 days.
View ANI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ANIP earnings forecast.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.64. The specialty pharmaceutical company earned $116.50 million during the quarter, compared to analyst estimates of $99.87 million. ANI Pharmaceuticals had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 15.77%. The business's revenue was up 57.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) EPS.

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).

ANI Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, August, 30th. The company provided earnings per share guidance of $3.62-4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425-445 million, compared to the consensus revenue estimate of $442.79 million.

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.87%), Rubric Capital Management LP (4.71%), Dimensional Fund Advisors LP (3.03%), William Blair Investment Management LLC (3.00%), Deep Track Capital LP (2.53%) and State Street Corp (2.71%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIP stock can currently be purchased for approximately $58.91.

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $1.20 billion and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

The company employs 600 workers across the globe.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.